Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 31, 2001
                                                 (May 29, 2001)

                             LASERSIGHT INCORPORATED
              Exact name of registrant as specified in its charter

                  State or other jurisdiction of incorporation

           0-19671                                              65-0273162
           -------                                              ----------
   Commission File Number                                    I.R.S. Employer
                                                            Identification No.

        3300 University Boulevard, Suite 140, Winter Park, Florida 32792
                     Address of Principal Executive offices

   Registrant's telephone number, including area code:      (407) 678-9900

Item 5.   Other Events

The press release issued by LaserSight Incorporated dated May 29, 2001 is
incorporated by reference herein.

Item 7.   Financial Statements, Pro Forma Financial Information and Exhibits.

          (c) Exhibits

          Exhibit 99     Press Release dated May 29, 2001


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                          LaserSight Incorporated

Date:   May 31, 2001                  By: /s/Michael R. Farris
                                           Michael R. Farris
                                           Chief Executive Officer

                                   EXHIBIT 99


        Winter Park, Florida, May 29, 2001 ---LaserSight Incorporated (NASDAQ:
LASE) today announced that it has entered into a Settlement and License
Agreement with VISX Incorporated (NYSE: EYE). Under the terms of the agreement
LaserSight has received a license to patents held by VISX that relate to
refractive excimer lasers, including United States Patents Nos. 4,718,418 and
B1 5,108,388 and has agreed to pay a royalty for each procedure performed in the
United States using a LaserSight refractive laser. As part of the agreement,
VISX purchased a fully paid up license to U.S. Patent No. 4,784,135 (the Blum

        In accordance with the terms of the Settlement and License Agreement,
the parties will file a stipulated order dismissing the patent infringement
action filed by VISX against LaserSight in November 1999 in the United States
District Court for the District of Delaware. This litigation was set for trial
in June 2001. Under the agreement, all economic terms and conditions are

        Michael R. Farris, president and chief executive officer of LaserSight,
stated, "We are very pleased to have settled this matter and to eliminate the
expense and distraction associated with the litigation. Our agreement with VISX
is another step in allowing our shareholders to realize the full value of our
state of the art technology. We will now be able to focus our management and
financial resources on the sales and development efforts for our LaserScan
LSX(R), UltraShaper(TM) keratome and AstraMax(TM) diagnostic work station."

        LaserSight is a leading provider of quality technology solutions and
innovative products for vision correction. The Company's products include the
LaserScan LSX precision microspot beam scanning system, its international
research and development activities related to the Astra family of products used
to perform custom ablation procedures known as CustomEyes(TM) and its
MicroShape(R) family of keratome products. The Astra family of products includes
the AstraMax diagnostic workstation designed to provide precise diagnostic
measurements of the eye and the AstraPro(TM) software, a surgical planning tool
that will utilize advanced levels of diagnostic measurements for the planning of
custom ablation treatments. The MicroShape family of keratome products includes
the UltraShaper durable keratome and UltraEdge(R) keratome blades.

        This press release contains forward-looking statements regarding future
events and future performance of the Company, which involve risks and
uncertainties that could materially affect actual results. Investors should
refer to documents that the Company files from time-to-time with the Securities
and Exchange Commission for a description of certain factors that could cause
the actual results to vary from current expectations and the forward looking
statements contained in this press release. Such filings include, without
limitation, the Company's Form 10-K, Form 10-Q and Form 8-K reports.